Baird analyst Joel Beatty lowered the firm’s price target on Leap Therapeutics to $20 from $30 and keeps an Outperform rating on the shares. The firm said they are positive on the update that all of the responses in CRC with DKN-01 announced last month have now been confirmed. This provides reassurance, around the 130-patient randomized controlled part B of the study that has now initiated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LPTX: